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ABSTRACT
PURPOSE: This study is a systematic literature review and meta-analysis concerning the use of a testosterone synthetic analog, 
oxandrolone, and its use in severe adult burns.
METHODS: Randomized prospective clinical studies, in English, Portuguese or Spanish, were sought on the following databases: 
MEDLINE, COCHRANE, EMBASE and LILACS. There was no restriction in relation to the publication date. 
RESULTS: This search produced 24 studies on MEDLINE and twelve articles were presented on the COCHRANE database .Sixteen 
were excluded due to the title not being related to this search or by including children. Of the eigth residual studies, after adaptation to 
the inclusion criteria, only four were selected. After analyzing the results, two were discarded since they did not present adequate patient 
characterization and the facts on these articles were analyzed differently from the others, hindering the meta-analysis.
CONCLUSION: The analysis of the available data demonstrated significant benefits (p<0.05) considering lesser loss of corporal mass, lesser 
nitrogen loss, and shorter donor area healing time, when Oxandrolone was used, comparatively with the control group (placebo or not).
Key words: Oxandrolone; Burns; Adults; Systematic review; Meta-analysis.
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Introduction
Burn injuries and their sequelae have been present 
for centuries as major importance world problems. It is 
referred that over 1.2 million individuals will sustain a burn 
injury every year in the USA, being that the majority of these 
lesions are small burns, treated in the ambulatory. However, 
approximately 60,000 cases are moderate or severe and require 
hospitalization for their treatment.  Furthermore, it is estimated 
that 5,000 deaths occur every year in the USA due to Burns or 
their complications1.
Corroborating to ratify the importance of the burn patient, 
and the need for improvements in their care, Bull and Fisher, in 
1949, reported a 50% mortality rate for children (0-14) with 49% 
TBSA, for young adults (15-44) with 46% TBSA, for individuals 
between 45 and 64 with a 27% TBSA and for those older than 65, 
10% TBSA2. These statistics have improved considerably with the 
advances in critical patients care, with current data showing a 50% 
mortality rate in children up to 14 with 98% TBSA and in young 
adults with over 75%TBSA3,4.
Data available through the Brazilian Burn Society 
indicate that, in Brazil, there are one million burn cases each year; 
200 thousand are seen in emergency services and 40 thousand will 
need hospital admission. Burns area amongst the main external 
death causes in Brazil, second only to other violent causes, such 
as traffic accidents and manslaughter5. A study on a hospital in 
Brasilia demonstrated a 6.2% death rate in burn patients admitted 
to an emergency hospital6.
As shown, it is noted the importance of the optimization 
of burn patient care in its acute phase, in intensive care, as well 
as in the recovering and rehabilitation phases, not forgetting that 
prevention is the best treatment.
Severe Burns will cause a great increment in catabolic 
rates, leading to lean mass consumption and decrease in protein 
reserve. Decreasing the lean mass will lead to a deficiency in 
wound healing and in muscle-skeletal function7-13. Testosterone 
analogs have been reported in the literature as substances which 
will decrease protein loss and stimulate anabolism14-18.
Oxandrolone is a synthetic analog, 17 alpha-methyl, 
derived from testosterone with frequent use in a large number of 
critical patients, such as advanced hepatopathies, HIV, cardiac 
cachexia, major Burns and other hyper catabolic patients, showing 
restoration in lean mass together with improved nutrition17-20.
However, few studies permeate oxandrolone anti-
catabolic action on major burn patients21-23. This action consists in 
diminishing protein and lean mass loss, shortening wound healing 
time and donor area reepithelisation, as well as possible hospital 
stay decrease16,17.
Based on the knowledge related to this subject, the 
objective of this systematic review study is to list the effects of 
oxandrolone in major adult burn patients, since there are few 
studies related to this theme on the literature, what rectifies 
the lack of protocol and systematization for its use in major 
burns units. As such, this review intends to serve as evidence 
for the secure and systematic use of Oxandrolone in the acute 
treatment as well as in the rehabilitation of adult patients with 
severe burns.
Objectives
The objective of this study is to respond the question 
about the use of oxandrolone in adult patients with severe burns, 
in relation to the time of wound healing of donor site, the nitrogen 
loss and the body mass loss.
Methods
To attain this objective, a selection of studies was 
performed within the main databases and its results were 
analyzed through a meta-analysis, according to the protocols of 
COCHRANE25.
Selection Criteria
For selection criteria, the search was performed within 
the main health databases: MEDLINE, COCHRANE, EMBASE 
e LILACS, the period of February 2014, using the key words: 
severe burn and oxandrolone. As filters, language was restricted to 
Portuguese, English and Spanish.
The first selection was done through reading the titles, 
excluding all articles which had children in the study. Later, other 
factor was the study design, being that clinical, randomized and 
prospective studies were selected.
As results, 
-  MEDLINE: the search produced 24 articles. Nine were 
excluded due to the title not being related to this search 
and seven were excluded because they included studies in 
children. Of the eight residual studies, two were literature 
reviews which were also excluded since they did not 
obey the inclusion criteria and six clinical trials, one was 
excluded for being retrospective and observational and 
other was selected to the systematic review. Of these five 
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articles, four were included in the systematic review and 
one excluded after reading the abstract because it was not 
about the subject of this review.
-  COCHRANE: 12 articles were presented: two systematic 
reviews were excluded for not being related to the search 
criteria of this research and ten controlled studies, of 
which five were exclude for being related to children 
or not corresponding to the theme. Four presented 
correspondence with those of MEDLINE
-  The other bases surveyed did not return any results.
Study Type
The four selected studies according to the search criteria 
were:
•  Demling R. (1999)21: Prospective, randomized, case 
controlled study
•  Demling R, Orgill PD. (2000)22: Prospective, randomized, 
double-blind, case controlled study
•  Demling R, DeSanti L. (2003)23: Prospective, 
randomized, case controlled study
•  Wolf SE et Col. (2006)24: Prospective, multicentre, 
randomized, double blind, case-controlled study
Study subjects
Subject groups, per study:
•  Demling R. (1999)21: Sequential patients who fitted the 
criteria for the use of anabolic agent, admitted to the 
burn center in 1996 and 1997. Patients were randomized 
either to a group using Human Growth Hormone (HGH) 
or Oxandrolone, The patients with major burns whom 
did not fit the inclusion criteria for either group were the 
control group.
The groups were characterized as such:
1.  Deep burns, 2nd or 3rd degree over 50% TBSA, with at 
least half of the area needing skin grafting.
2.  Deep burns, 2nd and 3rd degree over 25% TBSA, with 
comorbidities, such as: older than 60, malnutrition and 
adults with diabetes.
•  Demling R, Orgill PD. (2000)22: Sequential patients 
admitted to the burn center during 1998, which fitted the 
inclusion criteria. Patients were randomized in control 
and oxandrolone groups. Randomization was in a double 
blind pattern – caretakers did not know the groups, only 
the pharmacists. Criteria for inclusion were:
•  Patients with deep burns (2nd and 3rd degree) with 40 
to 70% TBSA, including those with inhalation injury 
and other comorbidities factors and at least 20% TBSA 
requiring grafting.
•  Demling R, DeSanti L. (2003)23: Patients with large 
burns whom were transferred to the Brigham and 
Women’s Hospital Burn Center between 1999 and 
2001. Patients were randomized in one group receiving 
physical exercises and optimized nutrition and one 
group receiving Oxandrolone and physical exercised 
and optimized nutrition. Patients with prostate or breast 
cancer history and with elevation of PSA were excluded 
from the study.
•  Wolf SE et al. (2006)24: Multicentric study in 14 Burn 
Centers. Inclusion criteria: patients of either sex, older 
than 18, with TBSA equal or greater to 20%. Patients fed 
orally or through enteral tube up to 5th day after burn and 
no associated injury (spinal injury, cerebral hypoxia, etc) 
Exclusion criteria: primary electrical or chemical injury, 
pregnancy, chronic liver disease, renal failure, cancer, 
recent or continuous use of steroids or anabolic agents 
and participation in other studies
Intervention Types
•  Demling R. (1999)21: Patients randomized in three groups 
according to criteria in 3.1.2 above, in three groups: 
Control Group (n=24) without the use of anabolic agents; 
HGH Group (n=20), with patients using HGH at 0.1 mg/
kg, intramuscularly, starting 7 to 10 days post-burn; 
and Oxandrolone Group (n=16) using Oxandrolone at 
20mg/day orally, starting 7 to 10 days post burn. All 
patients received optimized nutrition primarily based 
on the basal metabolic rate, according to the method of 
Wilmore et al.24. After the first week, required calories 
were adjusted according to indirect calorimetric and 
respiratory coefficient. Follow up was up to the transfer 
to a rehabilitation center, with resolution of the metabolic 
response to trauma, with clean wounds in less than 15% 
of burn surface area.
•  Demling R, Orgill PD. (2000)22: Patients devided into 
two randomized groups: Control Group (n=9), with 
similar characteristics ad the index group, using placebo 
pills containing 150mg of lactulose, corn extract and 
methyl-cellulose – four pills orally, twice a day, starting 
2 to 4 days post burn and Oxandrolone Group (n=11), 
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four pills, identical as the placebo ones, taken orally 
twice a day, starting 2 to 4 days post burn. These pills 
contained 2,5 mg Oxandrolone, 150 mg lactulose, corn 
extract and methyl cellulose. This regimen totaled 20 
mg Oxandrolone per day, which is the dose considered 
standard in the literature for critically ill patients17,18. 
Double blind study in which patients were accompanied 
until transferred to a rehabilitation unit. Transfers 
occurred when there was no longer a metabolic response 
to trauma; the wound has been cleaned and with less than 
10% total burn surface area (TBSA).
•  Demling R, DeSanti L. (2003)23: Patients with severe 
burns randomized in two groups: Control Group (n-22) 
with optimized nutrition and exercises; and Oxandrolone 
Group (n=23) – defined through inclusion criteria, whom 
received 20 mg Oxandrolone orally per day, in two 
dosages and optimized nutrition and exercises. Patients 
were followed regularly up to six months after no longer 
using Oxandrolone. 
•  Wolf SE et al. (2006)24: Patients who fitted the inclusion 
criteria were placed into groups according to age and% 
TBSA. In relation to age: 18-44, 45-64 adn over 65; in 
relation to burnt area: 20-30%, 31-40%, 41-50% and 51-
60% TBSA. After separating into these criteria, patient were 
randomized into two groups: Control Group (n=35) who 
received a pill containing sacarose and the Oxandrolone 
group (n=46) who received an identical pill in appearance, 
containing 10mg of Oxandrolone every 12 hours, orally 
or via tube, starting on the fifth day post burn extending 
to hospital discharge. Oral or enteral nutrition, surgical 
procedures for debridement or grafting were offered to 
all patients according to each institution criteria. Hepatic 
enzymes were measured when clinically indicated.
Revision Method
Clinical Assay Selection
Clinical assays were selected based in the analyzed data 
presenting the results of Oxandrolone use. With this aim, two studies 
were selected which presented enough information for the meta-
analysis. Demling R (1999)21 and Demling R, Orgill PD (2000)22. 
The third study Demling R, DeSanti L ( 2003)23 was excluded for 
not clearly defining the patient with severe burn, and also analyzing 
gain of body mass in the acute phase instead of loss. In relation 
to the fourth study, Wolf SE et al. (2006)24, it was not possible to 
compare its data via meta-analysis, because correspondence with 
the other studies were only in relation to length of hospital stay, and 
among the complications, hepatic enzymes analysis. 
Data Acquisition and Analysis
Data analysis was performed through meta-analysis 
using as comparison factors averages, standard deviations and 
number of individuals in each group of the selected studies. 
For data processing, an electronic tool known as 
“Comprehensive Meta Analysis”26 was used. It is virtually 
available for tests, correlation coefficient, odds ratio and Fisher Z 
relation calculations.
All data were displayed in tables and graphs (“florets 
plot”) for a better results visualization.
Results
Outcomes submitted to Meta-analysis
The analysis of the outcomes in this study, aiming at 
analyzing the effects of Oxandrolone use in major burn patients, 
identified the following aspects:
•  Donor area healing time
• Nitrogen balance
• Body mass loss
• Side-effects: liver toxicity, androgenic effect- hirsutism
• Metabolic rate
• Length of hospital stay
Meta-analysis results
Data analysis presented in table 1, 2 and 3, and their graphs 
respectively, demonstrate statistically significant benefits of the use of 
Oxandrolone, when compared to placebo, in relation to lesser body 
mass loss, lesser nitrogen loss, and lesser donor area healing time.
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Model Article Results Odds 
Ratio 
Logo
Standard 
Deviation
Confidence 
Interval
p value n-
Oxandrolone
n-
Control
Articler 
relative 
weight 
(fixed)
Article 
relative 
weight
(random)
Demling 
R. (1999)
Body mass 
lossl (Kg) (1)
3,421 0,699 2,051-4,792 0,000 16 24 12,32 10,37
Demling 
R. (1999)
Nitrogen loss 
(g/day) (2)
5,451 0,845 3,795-7,107 0,000 16 24 8,44 10,01
Demling 
R. (1999)
 Metabolic 
rate (%) (3)
-0,684 0,590 -1,841-0,473 0,247 16 24 17,28 10,62
Demling 
R. (1999)
Donor Area 
Healing time 
( days) (4)
3,628 0,712 2,232-5,023 0,000 16 24 11,88 10,34
Demling 
R. (1999)
Length of 
Stay (5)
-0,210 0,586 -1,359-0,938 0,719 16 24 17,55 10,62
Demling 
R, Orgill 
PD 
(2000)
Body mass 
loss (Kg) (6)
3,684 1,033 1,659-5,709 0,000 11 8 5,64 9,48
Demling 
R, Orgill 
PD 
(2000)
Nitrogen Loss 
(g/day) (7)
5,459 1,223 3,063-7,855 0,000 11 8 4,03 8,92
Demling 
R, Orgill 
PD 
(2000)
Metabolic 
rate(%) (8)
 
-0,267
0,844 -1,921-1,387 0,752 11 8 8,46 10,01
Demling 
R, Orgill 
PD 
(2000)
Donor Area 
Healing Time 
(days) (9)
2,948 0,969 1,048-4,847 0,002 11 8 6,42 9,67
Demling 
R, Orgill 
PD 
(2000)
Length of 
Stay (10)
-1,292 0,868 -2,994-0,411 0,137 11 8 7,99 9,95
Fixed(11) 1,648 0,245 1,167-2,129 0,000
Random 
(12)
2,147 0,800 0,579-3,716 0,007
TABLE 1 - Factors analyzed separately for each study, as body weight loss, nitrogen loss, metabolic rate, wound healing time of donor site 
and length of stay.
When metabolic rate and length of hospital stay are 
analyzed, there is no statistical difference. Metabolic rate is a 
normal response to burn injury and there was no difference on its 
increase between the two groups. Length of stay comparison was 
hindered because of the small number of patients and the lack of 
homogeneity amongst the groups.
Table 1/Figure 1 showed through Odds Ratio Log, 
that the difference among the analyzed factors had significance 
difference when they are analyzed separately in each study. 
Data on Table 2/Figure 2 showed the outcomes 
significance, through Correlation R meta-analysis, rectifying 
individual results.
Table 3/Figure 3 presented data comparison through 
Fisher Z Score, which corresponds to the linear relation among 
data of different studies.
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FIGURE 1 - Log Odds Ratio meta-analysis. CI – 95%.
Model Article Results Correlation Z 
value
Confidence 
Interval
p 
Value
n-
Oxandrolone
n-
Control
Article 
Relative 
Weight 
(fixed)
Article 
Relative 
Weight 
(random) 
Demling R. 
(1999)
Body mass 
loss (Kg) (1)
0,679 5,959 0,504-0,800 0,000 16 24 14,29 10,38
Demling R. 
(1999)
Nitrogen 
loss(g/day) 
(2)
0,827 9,196 0,730-0,892 0,000 16 24 16,72 10,47
Demling R. 
(1999)
Metabolic 
Rate (%) (3)
-0,182 -1,171 -0,455-0,123 0,242 16 24 11,19 10,22
Demling R. 
(1999)
Donor Area 
Healing TIme 
(days) (4)
0,700 6,310 0,535-0,813 0,000 16 24 14,57 10,40
Demling R. 
(1999)
Length of 
stay (5)
-0,057 -0,360 -0,351-0,248 0,719 16 24 11,02 10,21
Demling R, 
Orgill PD 
(2000)
Body mass 
loss (Kg) (6)
0,708 4,449 0,458-0,855 0,000 11 8 6,97 9,78
Demling R, 
Orgill PD 
(2000)
Nitrogen 
loss(g/day) 
(7)
0,830 6,389 0,677-0,914 0,000 11 8 7,97 9,92
Demling R, 
Orgill PD 
(2000)
Metabolic 
Rate 
Metabolic 
Rate (%) (8)
-0,072 -0,317 -0,479-0,360 0,751 11 8 5,24 9,43
Demling R, 
Orgill PD 
(2000)
Donor Area 
Healing Time 
(days) (9)
0,626 3,570 0,320-0,814 0,000 11 8 6,5 9,70
Demling R, 
Orgill PD 
(2000)
Length of 
Stay (10)
-0,332 -1,546 -0,654-0,092 0,122 11 8 5,53 9,50
Fixed (11) 0,534 11,364 0,457-0,604 0,000
Random (12) 0,471 2,770 0,148-0,702 0,006
TABLE 2 - Factors analyzed separately in each study for “R” correlation, as body weight loss, nitrogen loss, metabolic rate, cicatrization 
time of donor site and length of stay.
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FIGURE 2 - Meta-analysis for correlation (R). CI – 95%
Model Article Resultas Fisher’s 
Z
Standard 
Deviation
Confidence 
interval
p 
value
n-
Oxandrolone
n-
Control
Article 
relative 
weight 
(fixed)
Article 
relative 
weight 
(random)
Demling 
R. (1999)
Body mass loss 
(Kg) (1)
0,827 0,139 0,555-1,099 0,000 16 24 14,29 10,38
Demling 
R. (1999)
Nitrogen 
loss(g/day) (2)
1,179 0,128 0,928-1,431 0,000 16 24 16,72 10,47
Demling 
R. (1999)
Metabolic Rate 
(%) (3)
-0,184 0,157 -0,491-0,124 0,242 16 24 11,19 10,22
Demling 
R. (1999)
Donor Area 
Healing TIme 
(days) (4)
0,867 0,137 0,598-1,136 0,000 16 24 14,57 10,40
Demling 
R. (1999)
Length of stay 
(5)
-0,057 0,158 -0,366-0,253 0,719 16 24 11,02 10,21
Demling 
R, Orgill 
PD (2000)
Body mass loss 
(Kg) (6)
0,883 0,199 0,494-1,273 0,000 11 8 6,97 9,78
Demling 
R, Orgill 
PD (2000)
Nitrogen 
loss(g/day) (7)
1,187 0,186 0,823-1,551 0,000 11 8 7,97 9,92
Demling 
R, Orgill 
PD (2000)
Metabolic Rate 
Metabolic Rate 
(%) (8)
-0,073 0,229 -0,522-0,376 0,751 11 8 5,24 9,43
Demling 
R, Orgill 
PD (2000)
Donor Area 
Healing Time 
(days) (9)
0,734 0,206 0,331-1,138 0,000 11 8 6,50 9,70
Demling 
R, Orgill 
PD (2000)
Length of Stay 
(10)
-0,345 0,223 -0,782-0,092 0,122 11 8 5,53 9,50
Fixed (11) 0,596 0,052 0,493-0,699 0,000
Random (12) 0,511 0,184 0,149-0,872 0,006
TABLE 3 - Factors analyzed separately in each study to Fisher’s Z, as body weight loss, nitrogen loss, metabolic rate, cicatrization time of 
donor site and length of stay.
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FIGURE 3 – Fisher´s Z Score meta-analysis. CI – 95%
Discussion
Major burn patients (over 20%TBSA) represent a great 
challenge in their care and a great importance to society, when 
considering the seriousness of their acute phase and the lengthy 
sequelae treatment period, as well as the treatment cost and 
difficult physical and social rehabilitation1,2. 
As gathered from the literature, it becomes clear that as the 
percentage of body mass loss increases, so do the complications. 
A 10% body mass loss will lead to immune dysfunction; 20% to 
impaired wound healing; 30%, severe infections and 40%, death27. 
As the catabolism increases, it will also lead to a proportional 
increase in nitrogen loss.
It is well accepted that a shorter donor area healing 
time is imperative, since there are few donor areas in major burn 
patients. Obviously, the faster healing occurs, the faster skin can 
be re-harvested, and consequently more wounded areas covered.
Major burns will lead to an increase in catabolic rates, 
leading to lean mass use and decreased protein storage. Lean 
mass loss will lead to healing and muscle-skeletal impairment7-13. 
Testosterone analogs have been reported as substances which will 
lead to a lesser protein loss and to anabolism14-18.
Results in this study show that the use of Oxandrolone 
when compared to control (placebo or not) will lead to significant 
benefits, such as lesser body mass loss, lesser nitrogen loss and 
lesser donor area healing time.
The question mote for this meta-analysis has been 
answered in relation to the effects of Oxandrolone on the recovering 
of major burn patients. The benefits shown in each study and their 
results meta-analysis may serve as evidence for the introduction of 
this treatment in more burn centers which currently are not using 
it, possibly considering risks, which are not present in this study, 
in relation to this anabolic agent use.
Conclusion
Clinical Practice Implications
As this study has shown a lesser body mass loss, lesser 
nitrogen loss and lesser donor area healing time with this anabolic 
agent, we can suggest the adoption of Oxandrolone use for patients 
whom present with body mass loss, increase in nitrogen loss or 
hindered donor area or superficial burn wound healing.
Oxandrolone use in burn centers should be more frequent, 
in an attempt to create a better critically ill patient management 
protocol. This could lead to a shorter recovering and rehabilitation 
time, yielding benefits for the patient and minimize expense on the 
public health system. 
Study Limitations
It must be pointed out that there are only a small number 
of studies about the use of Oxandrolone in adults. There is a need 
for new randomized, double blind studies, with a larger number of 
patients so one could obtain quality evidence. The design should 
aim at demonstrating a possible shorter hospital stay, a smaller 
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incidence of complications, such as infection and the consequent 
use of antibiotics, as well as other factors like a shorter duration of 
orotracheal intubation. 
For this small number of studies, this study showed 
a meta-analysis of only two articles, even those of a center and 
conducted by the same investigator, which could adversely affect 
the results. However, the observance of the articles included in 
the systematic review, this can damage becomes relative, as all 
works reveal better patient outcomes with the use of oxandrolone, 
especially with regard to length of hospital stay endorsed at work 
multicenter Wolf SE et al. (2006)24.
A faster and better rehabilitation of the major burn patient 
and the optimization of his or her quality of life would be the main 
goal of these studies.
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